Print

Cytori Therapeutics, Inc. (CYTX) Release: Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan  
10/25/2012 9:59:51 AM

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) today announced two independent investigator-sponsored and funded cell therapy clinical studies in Japan have been approved by the Ministry of Health, Labor and Welfare under the Guidelines on Clinical Research Using Human Stem Cells. One study will investigate the use of Cytori’s cell therapy as a treatment for ischemic heart failure and the other as a treatment for cirrhosis of the liver. The studies will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate School of Medicine at Kanazawa University Hospital School of Medicine.